ReviewScience translational medicine2012
Pluripotent stem cells: immune to the immune system?
Review in Science translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Immunogenicity of autologous and allogeneic human primary cholangiocyte organoid cellular therapies.Cell reports. Medicine · 2025Article
- Review
- Microneedle-Mediated Cell Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Development of Biocompatible 3D-Printed Artificial Blood Vessels through Multidimensional Approaches.Journal of functional biomaterials · 2023Review
- Review
- iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors.Stem cell research & therapy · 2023Article
- Lessons from the Embryo: an Unrejected Transplant and a Benign Tumor.Stem cell reviews and reports · 2021Review
- Current Challenges and Solutions to Tissue Engineering of Large-scale Cardiac Constructs.Current cardiology reports · 2021Review
- iPSC for modeling neurodegenerative disorders.Regenerative therapy · 2020Review
- Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Human lung organoids develop into adult airway-like structures directed by physico-chemical biomaterial properties.Biomaterials · 2020Article
- Spermatogonial stem cells are a promising and pluripotent cell source for regenerative medicine.American journal of translational research · 2020Review
- Induced pluripotent stem cells as a novel cancer vaccine.Expert opinion on biological therapy · 2019Review
- Article
- Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Review
- Clodronate Improves Survival of Transplanted Hoxb8 Myeloid Progenitors with Constitutively Active GMCSFR in Immunocompetent Mice.Molecular therapy. Methods & clinical development · 2017Article
- CRISPR-Cas Genome Surgery in Ophthalmology.Translational vision science & technology · 2017Review
- Induced pluripotent stem cell technology: a decade of progress.Nature reviews. Drug discovery · 2017Review
- Efficient Generation of Functionally Active Spinal Cord Neurons from Spermatogonial Stem Cells.Molecular neurobiology · 2017Article
- Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review.JAMA cardiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Human embryonic stem cells (hESCs), initially thought to be immune privileged cells, are now known to be susceptible to immune recognition. Human induced pluripotent stem cells (iPSCs) have been proposed as a potential source of autologous stem cells for therapy, but even these autologous stem cells may be targets of immune rejection. With clinical trials on the horizon, it is imperative that the immunogenicity of hESCs and iPSCs be definitively understood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.